Advancing Targeted Radionuclide Therapy Through the National Cancer Institute's Small Business Innovation Research Pathway.
J Nucl Med
; 60(1): 41-49, 2019 01.
Article
em En
| MEDLINE
| ID: mdl-30030338
ABSTRACT
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Cancer Institute (NCI) are congressionally mandated set-aside programs that provide research funding to for-profit small businesses for the development of innovative technologies and treatments that serve the public good. These two programs have an annual budget of $159 million (in 2017) and serve as the NCI's main engine of innovation for developing and commercializing cancer technologies. In collaboration with the NCI's Radiation Research Program, the NCI SBIR Development Center published in 2015-2017 three separate requests for proposals from small businesses for the development of systemic targeted radionuclide therapy (TRT) technologies to treat cancer. TRT combines a cytotoxic radioactive isotope with a molecularly targeted agent to produce an anticancer therapy capable of treating local or systemic disease. This article summarizes the NCI SBIR funding solicitations for the development of TRTs and the research proposals funded through them.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
National Cancer Institute (U.S.)
/
Terapia de Alvo Molecular
/
Empresa de Pequeno Porte
/
Invenções
/
Neoplasias
Limite:
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
J Nucl Med
Ano de publicação:
2019
Tipo de documento:
Article